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Abstract 
Background: Although the age range of chronic obstructive pulmonary disease (COPD) patients is broad, few stud-
ies have focused on the effects of age on disease characteristics.
Methods: Keio University and affiliated hospitals established an observational COPD cohort. Patients were assessed 
using high resolution computed tomography (CT) to quantify emphysema, health status using the COPD assessment 
test (CAT) and the St. George’s Respiratory Questionnaire (SGRQ), spirometry, echocardiogram, dual X-ray absorption 
of bone, biomarkers and comorbid diagnoses. We examined the characteristics of COPD patients aged 75 and over 
compared with patients below 75.
Results: A total of 443 patients comprising 252 patients aged <75 years and 191 patients aged ≥75 years, were 
enrolled. Emphysematous changes on CT and prevalence of possible pulmonary hypertension were greater in late-
elderly patients. The slope of the relationship between CT emphysema densitometry score and forced expiratory 
volume in 1 s was significantly less steep in the late-elderly than the younger patients (p = 0.002). CAT and total SGRQ 
scores and the frequency of long-term oxygen therapy were significantly higher in the late-elderly with moderate 
airflow obstruction compared to those of the younger in the same grade, although the opposite was seen in late-
elderly patients with very severe airflow obstruction. Hypertension, aortic aneurysm, prostatic hypertrophy, anemia, 
and cataract are more prevalent in late-elderly patients.
Conclusions: Elderly COPD patients show a varied age-related pattern of disease that warrants specific attention in 
clinical practice above and beyond assessment of airflow limitation.
Trial registration Clinical trial registered with the University Hospital Medical Information Network (UMIN000003470, 
April 10, 2010)
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Background
Chronic obstructive pulmonary disease (COPD), one of 
the most prevalent health conditions, is the fourth lead-
ing cause of death worldwide [1]. COPD morbidity and 
mortality have been increasing in many countries, in part 
due to an aging population world-wide [2]. By the mid-
21st century, the chance of living beyond 60  years will 
be 98 % in Japan/Oceania, 82 % in Western Europe, and 
69 % in China [3]. Relative to the 2011 world population, 
recent United Nations projections estimate that by 2100 
the number of people aged >60 years will triple, with an 
eightfold increase in those >80 [1]. However, although 
increases in life expectancy and the size of the elderly 
population during the past several decades might explain 
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the current increase in COPD, the relationship may be 
more complex, including factors such as differential sus-
ceptibility to tobacco, anatomic and systemic differences, 
behavioral differences, and differences in response to 
available therapeutic modalities.
Japan is a super-aged society, ranked first in the world. 
The late elderly (aged ≥75 years) accounted for 11.6 % of 
Japan’s population in the 2010 national population cen-
sus. In recent years pulmonary and primary care physi-
cians in Japan have been more ready to diagnose and 
treat COPD patients of advanced age, and although it is 
known that COPD currently mostly affects middle-aged 
and elderly people, few studies have focused on how the 
features of COPD differ by age.
In the past, COPD severity was simply classified based 
upon the % forced expiratory volume in 1 s (FEV1), 
because it was believed that the majority of patients fol-
lowed a path of disease progression in which the severity 
of the disease tracked the severity of the airflow limita-
tion [4]. However, it has become clear in recent years that 
comprehensive assessment requires more than FEV1 
measurement. The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) has proposed an assessment 
for COPD treatment based on the patient’s level of symp-
toms and future risk of exacerbation, in addition to the 
severity of spirometric abnormality [5].
Very elderly patients with COPD may present differ-
ently from younger ones; they may have a different pat-
tern of comorbidities, and a different survival rate after 
acute exacerbations. Physicians may also have an age bias 
that may affect both diagnosis and treatment. The pur-
pose of this study was thus to examine the characteristics 




Keio University and affiliated hospitals have estab-
lished an observational COPD cohort, registered with 
the University Hospital Medical Information Network 
(UMIN000003470), for investigations of the management 
of COPD comorbidities [6]. All patients were clinically 
stable without exacerbations for at least 1 month prior to 
study. The protocol was approved by the Ethics Commit-
tees of Keio University on July 29, 2009 (No. 20090008) 
and the affiliated hospitals, and written informed consent 
was obtained from each patient.
Measurement of pulmonary functions
All participants underwent spirometry when in a sta-
ble condition during the baseline examination, accord-
ing to ATS protocols using an electronic spirometer [7]. 
Predicted values were derived from the guidelines for 
pulmonary function tests issued by the Japanese Respira-
tory Society [8]. The classification of disease severity was 
based on GOLD spirometric grading [2], Grade I: mild 
(FEV1/forced vital capacity (FVC) <0.70, %FEV1 ≥80 %), 
Grade II: moderate (FEV1/FVC <0.70, %FEV1 50–80 %), 
Grade III: severe (FEV1/FVC <0.70, %FEV1 30–50 %) and 
Grade IV: very severe COPD (FEV1/FVC <0.70, %FEV1 
<30 %).
Assessment of clinical parameters
At enrollment, a full medical and smoking history and 
current pharmacological treatment were obtained 
and clinical examinations were performed. Comorbid 
diagnoses were established using clinical history and 
examination findings, supported by a review of avail-
able medical records. The Hospital Anxiety and Depres-
sion Scale (HADS) was used, with a cut-off score of 11 
points each for a probable status of anxiety or depression 
[9]. Gastro-esophageal reflux disease (GERD) symptoms 
were evaluated using a self-reported Frequency Scale for 
the Symptoms of GERD (FSSG) questionnaire, consist-
ing of 12 items, with a cut-off score of 8 points for GERD 
[10].
Questionnaires on health‑related quality of life (QOL)
Each patient’s health-related QOL was evaluated using 
three questionnaires. Two were disease-specific: the 
COPD Assessment Test (CAT) and St George’s Respira-
tory Questionnaire (SGRQ) [11–14]. The CAT has been 
validated in Japan using the same population enrolled 
in the present study [6]. The Medical Outcomes Study 
Short-Form 36-Item (SF-36) version 2 was also used to 
measure the patients’ general health status [15, 16], and 
it was reported that COPD patients have SF-36 lower 
scores, representing worse health-related QOL [17]. All 
of the questionnaires were completed by the patients 
themselves, at home, in the stable state.
Evaluation of emphysema on CT scan
Quantitative High Resolution computed tomography 
(HRCT) analyses of emphysema were performed. Low-
attenuation areas (LAAs) using a threshold level of −950 
HU were determined using a Discovery CT 750HD CT 
system (GE Healthcare, Tokyo), adjusting the threshold 
on each model of CT scan using a CT scanner test object, 
the Multipurpose Chest Phantom N1 “Lungman” (Kyoto 
Kagaku, Kyoto, Japan) [18] and calculated its percentage 
relative to the entire lung area (LAA%) using the work-
station Lexus 64® (AZE Ltd., Tokyo) [19].
Echocardiographic evaluation
Echocardiograms were obtained using two commercially 
available echocardiography systems (GE Vivid7/Vivid9, 
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GE Healthcare, Horten, Norway and iE33/Sonos7500, 
Philips; Amsterdam, Netherlands). A 2.5-MHz trans-
ducer was used to obtain the images in the paraster-
nal and apical views, corresponding to the standard 
long-axis, and two-chamber and four-chamber images, 
respectively. Standard two-dimensional and color Dop-
pler data were collected. The estimated systolic pul-
monary artery pressure (eSPAP) was calculated [20], 
and pulmonary arterial hypertension was defined by an 
eSPAP ≥35 mmHg [21].
Statistical analysis
All data are expressed as mean, unless otherwise stated. 
Student’s t test was performed to compare mean values 
between the two groups. Comparisons of data among 
the four patient groups were performed using analysis of 
variance (ANOVA), followed by a Tukey–Kramer post 
hoc analysis. Comorbidities were included as a categori-
cal variable. A χ2 analysis was conducted to compare the 
frequencies between two groups. Relationships between 
quantitative data were examined using Spearman tests. 
Analysis of covariance (ANCOVA) were conducted to 
examine whether the slope of the relationship between 
two parameters differed between the patients aged <75 
and ≥75 years. P values less than 0.05 were considered 
significant. All data were analyzed using the JMP version 
9.0.2 software for Windows.
Results
Demographic measures
The mean age of the 443 COPD patients was 72.6 ± 8.2 
SD years (range 43–91 years), and 92 % were males. The 
clinical characteristics of the subgroups of late-elderly 
patients (aged ≥75 years) and relatively younger patients 
(aged <75  years) are tabulated (Table  1). There was no 
significant difference between the two subgroups in 
smoking amount, BMI, proportion of the GOLD grades, 
and their treatment with medication. Current smokers 
were more prevalent in the younger patients.
Numbers, mean (SD), and median (range) of age in 
GOLD grades I to IV were as follows; I: n  =  93, 71.6 
(8.2), 73 (49–89), II: n = 202, 72.9 (8.6), 73 (43–91), III: 
n = 115, 72.9 (7.7), 74 (51–89), IV: n = 33, 72.3 (7.9), 74 
(54–89). There was no significant difference in age among 
the GOLD grades.
Vital capacity (VC) and FEV1 by GOLD grade
An individual’s VC and FEV1 are expected to fall with 
increasing age, premised on the repeated findings that 
respiratory function worsens with age. In GOLD grades 
I–III, the VC and FEV1 values were significantly lower 
in the late-elderly patients compared to the younger 
patients, but among the GOLD grade IV patients there 
was no difference between the two groups (Fig. 1a, c). In 
contrast, the mean VC % predicted and FEV1 % predicted 
were not lower in the late-elderly patients compared to 
the younger patients when grouped by GOLD grade 
(Fig. 1b, d).
Age‑related difference in the relationship 
between emphysema on CT scan and FEV1
CT scans were performed on 246 patients enrolled at 
Keio University Hospital. Overall, there was a signifi-
cant correlation between the degree of emphysema and 
%FEV1 (r = −0.453, p < 0.0001), but in the patients aged 
<75 years, the slope of the relationship between these two 
variables was significantly steeper than in patients aged 
>75 (ANCOVA, p = 0.002) (Fig. 2).
Age‑related difference in the prevalence of pulmonary 
hypertension
Echocardiography was performed on 265 patients 
enrolled at Keio University Hospital, and the eSPAP was 
measurable for 179 of these patients (72.8  %). Among 
the GOLD grade II patients, the prevalence of possible 
Table 1 Demographic data of the COPD patients (n = 443)
BMI body mass index, VC vital capacity, FEV1 forced expiratory volume in 1 s, 
GOLD Global Initiative for Obstructive Lung Disease, LTOT long-term oxygen 
therapy, CAT COPD assessment test, SGRQ St George’s Respiratory Questionnaire, 
n.s. not significant
Age <75 years Age ≥75 years p value
No. of subjects 252 191
Age (mean, years) 66.9 80.0
Sex (male/female) 231/21 175/16 n.s.
Smoking amount (mean, 
pack-year)
56.9 55.6 n.s.
Current smoker (%) 17.3 7.7 0.004
BMI (mean, kg/m2) 22.5 22.3 n.s.
VC (mean, ml) 3365 2934 <0.001
VC (mean, % predicted) 93.8 93.5 n.s.
FEV1 (mean, ml) 1717 1465 <0.001
FEV1 (mean, % predicted) 60.5 62.1 n.s.
GOLD grade (I/II/III/IV) 52/114/67/19 41/88/48/14 n.s.
LTOT (%) 10.7 15.9 n.s.
CAT (mean) 12.5 12.7 n.s.
SGRQ symptom (mean) 36.5 37.9 n.s.
SGRQ activity (mean) 39.7 47.5 0.001
SGRQ impact (mean) 18.3 22.3 0.04
SGRQ total (mean) 27.4 32.2 0.02
Oral corticosteroids (%) 3.2 3.6 n.s.
Inhaled corticosteroids (%) 35.0 32.8 n.s.
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pulmonary hypertension was significantly higher in the 
late-elderly patients compared to the younger patients. 
(28.2 vs. 7.5 %, p =  0.02) (Fig. 3a). After controlling for 
differences in LAA % between the two groups of patients, 
patients ≥ 75 years had a higher level of eSPAP (31.9 vs. 
27.1 mmHg, p = 0.001) (Fig. 3b).
Age‑related difference in health‑related QOL
The CAT score increased (worsened) with worsening 
GOLD grade in the younger COPD patients (p < 0.0001); 
this was largely due to the very high score in the younger 
patients in GOLD Grade IV. There was no overall signifi-
cant difference in CAT score between GOLD grades in the 
late-elderly COPD patients (p = 0.15) (Fig. 4). Differences 
between elderly and younger patients were inconsistent 
across the GOLD grades. The same pattern seen with the 
CAT were also seen in with SGRQ scores (compare Fig. 4 
with Fig. 5), and with the generic questionnaire, the SF-36 
(Additional file 1: Figure S1, Additional file 2: Figure S2).
Age‑related variability in the introduction of long‑term 
oxygen therapy (LTOT)
There was no significant difference in the ratio of patients 
receiving LTOT between the younger and late-elderly 
COPD patients as a whole (Table 1), although there was 
a pattern of more LTOT use in the late-elderly patients 
in GOLD Grades I-III, but significantly less in GOLD IV 
patients (Table 2), perhaps because of the combined mor-
tality impact of age, severe airflow limitation and severe 
hypoxia.
Differences in the frequency of comorbidities by age
Some comorbidities including hypertension (46.5 
vs. 29.6  %, p  <  0.01), aortic aneurysm (6.6 vs. 1.7  %, 
p  <  0.05), prostatic hypertrophy (19.7 vs. 7.7  %, 
p < 0.01), anemia (37.2 vs. 15.7 %, p < 0.01), and cata-
ract (64.1 vs. 34.8 %, p < 0.01) were significantly more 
prevalent in the late-elderly compared to the younger 
patients (Table 3).
Fig. 1 Comparisons of VC and FEV1 values between COPD patients aged <75 and ≥75 years with different grades of COPD. a VC, b %VC, c FEV1, d 
%FEV1. Gray columns <75 years old, Black columns ≥75 years old. Data are presented as mean ± standard deviation (SD). *p < 0.05
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Discussion
Japan became a super-aged society before other coun-
tries, but this trend is present in all developed and in 
developing countries [1]. The results of the present 
study suggest that COPD patients surviving to become 
late-elderly have a different pattern of lung function 
disturbance and emphysema to those who are younger. 
Although a strong correlation of emphysema on CT scan 
with spirometry was found in a large-scale cohort [22], 
the severity of emphysema varies widely even among 
patients with the same grade of COPD [19], our data 
suggests that age may be a factor in that variation. One 
of the problems in comparing different ages of COPD 
patients is the reliability of estimates of normal ranges 
for FEV1 in the late-elderly. VC and FEV1 are thought 
to decline linearly with age; this being the basis of equa-
tions for calculating predicted values based on age. In 
the present study, late-elderly COPD patients showed 
lower VC and FEV1 values compared to those in the 
younger patients, but they were classified in the same 
grade of COPD based on percentage of predicted values. 
These observations imply that VC and FEV1 were sim-
ilarly reduced by age across the grades of airflow limi-
tation in patients with COPD to those in the Japanese 
general population. The less steep slope of the relation-
ship between emphysema and FEV1 shown in Fig. 2 may 
be due to a healthy survivor effect (late elderly patients 
with severe airflow limitation being more likely to die), 
but relationships between the severities of airflow limita-
tion and emphysema can be different in the late-elderly 
and younger patients with COPD.
We compared health-related QOL using the CAT, 
SGRQ and SF-36 between the two groups at different 
levels of airflow limitation. Overall there was a weak 
but generally consistent trend towards patients with 
more severe airflow limitation having worse QOL. To 
the authors’ best knowledge, no previous studies have 
focused on the age-related differences of health-related 
QOL in patients with COPD. Age negatively affects phys-
ical function, physical role limitations and general health 
[23] and our study reports similar findings, although we 
have shown that late-elderly patients in GOLD IV have 
better health status than younger patients. This may 
reflect a healthy survival effect, since the proportion of 
late elderly patients GOLD IV who were on LTOT was 
much lower than in the younger patients with the same 
degree of airflow limitation. This conclusion was sup-
ported by the data on pulmonary hypertension, since for 
any given degree of airflow limitation, the late-elderly 
patients were more likely to have pulmonary hyperten-
sion, except in GOLD IV. We have previously reported 
that comorbid diseases such as depression, anxiety, and 
GERD may increase CAT scores [3]. However, there was 
no difference in the prevalence of such comorbidities 
between the late-elderly and younger patients. In con-
trast age-related comorbid diseases including hyperten-
sion, aortic aneurysm, prostatic hypertrophy, anemia, 
and cataract were not associated with CAT scores in the 
present study (data not shown).
One of the strengths of our cohort study is that the 
study population is a community-living sample. The 
patients enrolled provide a representative range of the 
socio-economic characteristics of COPD patients in 
Japan, registered at a general clinical practice, a university 
hospital or a related facility. Coincidentally, other COPD 
cohort studies conducted in different Japanese locality 
investigated participants with a similar average age [24, 
25]. Indeed, COPD patients in Japan are typically elderly, 
and there might be a “healthy survivor effect” in their 
late seventies and beyond. We speculate that these older-
aged COPD cohorts contain a higher proportion of peo-





























Fig. 2 Correlation between %FEV1 and LAA % in each age group. 
a Gray circles <75 years old, b black circles ≥75 years old. *p = 0.002 
comparison of the slopes between two different age groups
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serious or life-threatening comorbid problems as their 
younger peers. We have no reason to believe that the pat-
tern seen in these COPD patients is a particularly Japa-
nese phenomenon.
As COPD is more prevalent at older ages, it repre-
sents an increasing problem for public healthcare world-
wide. Few studies have reported the clinical features of 
COPD in very elderly patients [26, 27], and the need for 
more research into the impact of age on this growing 
subpopulation of COPD patients is urgent [28]. Our 
study identified late-elderly COPD patients with moder-
ate airflow limitation who manifested severe emphysema 
and/or pulmonary hypertension, and disabling dyspnea 
that were not usually complicating features of COPD 
patients with moderate airflow limitation for the younger 
patients. In part this may be because the conventional 
%FEV1 staging scheme may be misleading as a measure 
of severity in late-elderly patients [29]. An alternative 
staging strategy that accounted for age-related changes in 
pulmonary function and variability in spirometric perfor-
mance, i.e., the lambda-mu-sigma method, demonstrated 
that 28.1 % of patients with severe COPD were classified 
as moderate using the standard GOLD grades [30].
One limitation of this study is the lack of age-matched 
healthy controls for comparison, although that is compli-
cated by the fact that the elderly often live with one or 
more chronic conditions [31]. Another limitation is that 
the objective quantification of emphysema severity and 
pulmonary hypertension was not assessed for all of the 
enrolled subjects, because we had to use different types 
of CT scanners and echocardiography systems in each 
affiliated hospital. Finally, this study mainly consisted of 
male patients (91.6 %), and further investigations are nec-
essary to test whether our observations are applicable to 
female COPD patients.
Fig. 3 Relationships between pulmonary hypertension and age. 
a Comparisons of prevalence of possible pulmonary hypertension 
(eSPAP ≥35 mmHg) between COPD patients aged <75 and ≥75 
years in different stages of COPD, *p = 0.02, b comparisons of eSPAP 
between COPD patients aged <75 and ≥75 years after controlling for 
differences in LAA %. Data are presented as mean ± SD. *p = 0.001
Fig. 4 Total CAT scores of COPD patients aged <75 and ≥75 years 
with different GOLD grades of COPD. Gray columns <75 years old, 
black columns ≥75 years old. Data are presented as mean ± SD. 
*p < 0.05 between two different age groups. p < 0.0001 comparison 
between four GOLD grade groups of <75 years old, and †p < 0.05 by 
post hoc analysis between Grade IV vs. I, II, and III groups
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Conclusion
The present study demonstrates that very elderly indi-
viduals present a different pattern of COPD than younger 
patients. This is possibly the result of different pathways 
of disease coupled with a healthy survivor effect. Assess-
ments of COPD severity from a multidimensional per-
spective are essential for the appropriate attribution of 
symptoms and use of COPD-directed therapies. The 
results of the present study further strengthen the need 
for a better assessment of airflow limitation in late-elderly 
Fig. 5 Comparisons of SGRQ scores between COPD patients aged <75 and ≥75 years in different grades of COPD. a Symptom scores, b activity 
scores, c impact scores, d total scores. Data are presented as mean ± SD. *p < 0.05. p < 0.001 comparison between four GOLD grade groups of <75 
years old, and †p < 0.05 by post hoc analysis between Grade IV vs. I, II, and III groups (a–d). p < 0.001 comparison between four GOLD grade groups 
of ≥75 years old, and †p < 0.05 by post hoc analysis between Grade IV vs. I and II groups (b), Grade IV vs. I group (c, d)
Table 2 Prevalence of  LTOT among  COPD patients  <  75 
and ≥ 75 years old
n.s. not significant
Prevalence (%) p value
<75 years old ≥75 years old
I 1/52 (1.9 %) 3/41 (7.3 %) n.s.
II 4/114 (3.5 %) 13/88 (14.8 %) 0.0043
III 7/67 (10.4 %) 11/48 (22.9 %) n.s.
IV 14/19 (73.7 %) 2/14 (14.3 %) 0.002
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patients than current FEV1 prediction values and late-
elderly COPD patients warrant specific attention in clini-
cal practice.
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